ES2096207T3 - Prevencion y tratamiento de aterosclerosis. - Google Patents
Prevencion y tratamiento de aterosclerosis.Info
- Publication number
- ES2096207T3 ES2096207T3 ES93303526T ES93303526T ES2096207T3 ES 2096207 T3 ES2096207 T3 ES 2096207T3 ES 93303526 T ES93303526 T ES 93303526T ES 93303526 T ES93303526 T ES 93303526T ES 2096207 T3 ES2096207 T3 ES 2096207T3
- Authority
- ES
- Spain
- Prior art keywords
- arteriosclerosis
- present
- patient
- treatment
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000001320 Atherosclerosis Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 4
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCION PRESENTA UN METODO PARA EL TRATAMIENTO DE LA ARTERIOSCLEROSIS. EL METODO COMPRENDE EL PASO DE ADMINISTRAR A UN PACIENTE QUE TIENE ARTERIOSCLEROSIS, UNA COMPOSICION DE NO CISTEINA, DE NO TIOL QUE ESTIMULARA LA SINTESIS INTRACELULAR DE GLUTATION. EN UNA REALIZACION, LA COMPOSICION DE NO CISTEINA, NO TIOL ES L EN UNA REALIZACION DE LA PRESENTE INVENCION, LA PRESENTE INVENCION PROPORCIONA UN METODO PARA PREVENIR LAS LESIONES DE ARTERIOSCLEROSIS EN UN PACIENTE CON RIESGO DE LA MISMA. ADEMAS, LA PRESENTE INVENCION SE REFIERE A UN METODO PARA PREVENIR REESTENOSIS EN UN PACIENTE QUE PADECE UN PROCESO INVASIVO PARA TRATAR LA ARTERIOSCLEROSIS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/930,183 US5306724A (en) | 1992-08-17 | 1992-08-17 | Method for preventing and treating atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2096207T3 true ES2096207T3 (es) | 1997-03-01 |
Family
ID=25459031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93303526T Expired - Lifetime ES2096207T3 (es) | 1992-08-17 | 1993-05-06 | Prevencion y tratamiento de aterosclerosis. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5306724A (es) |
| EP (1) | EP0583865B1 (es) |
| JP (1) | JPH06172175A (es) |
| AU (1) | AU663373B2 (es) |
| CA (1) | CA2103644A1 (es) |
| DE (1) | DE69306335T2 (es) |
| ES (1) | ES2096207T3 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208249A (en) * | 1992-08-20 | 1993-05-04 | Clintec Nutrition Co. | Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate |
| US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| US5380747A (en) * | 1992-10-30 | 1995-01-10 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| US5821260A (en) * | 1992-10-30 | 1998-10-13 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| US5925658A (en) * | 1995-03-02 | 1999-07-20 | Sankyo Company, Limited | Optically active thiazolidinone derivative |
| US5792787A (en) * | 1995-06-07 | 1998-08-11 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| AU7252896A (en) * | 1995-10-02 | 1997-04-28 | Trustees Of Columbia University In The City Of New York, The | Biochemical markers of ischemia |
| WO1998009620A1 (en) * | 1996-09-05 | 1998-03-12 | Research Development Foundation | INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN |
| EP1223948A2 (en) * | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
| CN104411316B (zh) | 2012-05-09 | 2018-05-01 | 坎泰克斯制药股份有限公司 | 骨髓抑制的治疗 |
| US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53119866A (en) * | 1977-03-25 | 1978-10-19 | Yoshitomi Pharmaceut Ind Ltd | 5-aryloxy-oxazoleakanoic acid derivatives and their preparation |
| US4665082A (en) * | 1981-02-11 | 1987-05-12 | Cornell Research Foundation | Cysteine delivery system |
| US4647571A (en) * | 1981-02-11 | 1987-03-03 | Cornell Research Foundation | Cysteine delivery composition |
| US4710489A (en) * | 1985-04-22 | 1987-12-01 | Cornell Research Foundation, Inc. | Glutathione delivery system |
| DE3722647A1 (de) * | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | Galenische verwendung eines tripeptids als arzneimittel |
| EP0842925A1 (en) * | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| US4791125A (en) * | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
| US4798835A (en) * | 1987-12-02 | 1989-01-17 | Pfizer Inc. | dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent |
| US5095027A (en) * | 1991-02-28 | 1992-03-10 | Clintec Nutrition Co. | Method for treating reperfusion injury employing L-2-oxothiazolidine-4-carboxylic acid |
-
1992
- 1992-08-17 US US07/930,183 patent/US5306724A/en not_active Expired - Fee Related
-
1993
- 1993-05-05 AU AU38387/93A patent/AU663373B2/en not_active Ceased
- 1993-05-06 EP EP93303526A patent/EP0583865B1/en not_active Expired - Lifetime
- 1993-05-06 DE DE69306335T patent/DE69306335T2/de not_active Expired - Fee Related
- 1993-05-06 ES ES93303526T patent/ES2096207T3/es not_active Expired - Lifetime
- 1993-08-09 CA CA002103644A patent/CA2103644A1/en not_active Abandoned
- 1993-08-17 JP JP5203491A patent/JPH06172175A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU663373B2 (en) | 1995-10-05 |
| EP0583865B1 (en) | 1996-12-04 |
| JPH06172175A (ja) | 1994-06-21 |
| DE69306335T2 (de) | 1997-05-28 |
| DE69306335D1 (de) | 1997-01-16 |
| US5306724A (en) | 1994-04-26 |
| EP0583865A1 (en) | 1994-02-23 |
| AU3838793A (en) | 1994-02-24 |
| CA2103644A1 (en) | 1994-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT100279A (pt) | Utilizacao de difenilbutilpiperazinocarboxamidas na presenca de composicoes farmaceuticas para o tratmento de perturbacoes provocadas por abuso de drogas em pacientes viciados e processo de tratamento que as emprega | |
| ATE205086T1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
| BR9407720A (pt) | Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto | |
| MD990262A (en) | Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease | |
| DE69530594D1 (de) | Verfahren und mittel zur arzneistoffverabreichung | |
| MX9701385A (es) | Preparacion de producto combinado para usarse en enfermedades inmunologicas. | |
| BG97678A (en) | Beta -carotene and/or vitamin e therapy for inhibition of major vascular events | |
| ES2096207T3 (es) | Prevencion y tratamiento de aterosclerosis. | |
| WO1994008551A3 (en) | Pharmaceutical compositions and methods for treating cold symptoms | |
| BG100510A (bg) | Метод за лечение на андрогенна алопеция с инхибитори на 5-алфа редуктаза | |
| BR9509006A (pt) | Composiçao para aplicaçao tópica na pele composiçao farmacêutica uso de um inibidor de síntese de colesterol e processo para o tratamento mitigaçao ou prevençao de distúrbios de pele | |
| PT758241E (pt) | Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses | |
| ES2098920T3 (es) | Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina. | |
| UA35611C2 (uk) | Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри | |
| BR9907770A (pt) | Mistura sinérgica de produtos naturais e seu uso | |
| PT1102586E (pt) | Utilizacao de extractos de ginkgo biloba para a preparacao de um medicamento para o tratamento da esclerose lateral amiotrofica | |
| MX9703944A (es) | Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis. | |
| ATE315936T1 (de) | Medikamente zur verhinderung von eingriffsbedingter stenose als folge von nicht- bypass invasiver eingriffe | |
| EP1037918A4 (en) | METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES | |
| MX9304185A (es) | Producto y composicion farmaceutica que lo contiene para el tratamiento de la mastitis y la mestritis bovina. | |
| BR9406865A (pt) | Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica | |
| NO975177L (no) | Farmasöytiske sammensetninger for behandling av alkoholavhengighet | |
| DE69424679D1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
| DE69525631D1 (de) | Verwendung von prostaglandinen zur herstellung eines arzneimittels zur prävention und behandlung des sekundären katarakts | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 583865 Country of ref document: ES |